FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117299097> ?p ?o ?g. }

• W2117299097 endingPage "254" @default.
• W2117299097 startingPage "247" @default.
• W2117299097 abstract "To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer.The EPC programme comprises three randomized, double-blind, placebo-controlled trials designed for combined analysis. Following standard care, 8113 men with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N+) prostate cancer (all M0) received oral bicalutamide 150 mg once daily or oral placebo. The primary endpoints were progression-free survival (PFS) and overall survival.The large EPC trial programme is defining men who benefit or do not from early or adjuvant antiandrogen therapy. At a median follow-up of 7.4 years, in localized disease there is no benefit to PFS by adding bicalutamide to standard care, and there is a trend (hazard ratio, HR, 1.16; 95% confidence intervals, CI, 0.99-1.37; P = 0.07) towards decreased survival in patients otherwise undergoing watchful waiting. However, in locally advanced disease, bicalutamide significantly improved PFS irrespective of standard care. Bicalutamide significantly improved overall survival in patients receiving radiotherapy (HR 0.65; 95% CI 0.44-0.95; P = 0.03); this was driven by a lower risk of prostate cancer-related deaths. Bicalutamide produced a trend towards improved overall survival in patients with locally advanced disease otherwise undergoing watchful waiting (HR 0.81; 95% CI 0.66-1.01; P = 0.06). No survival difference was evident in the prostatectomy subgroup.This ongoing programme is clarifying the role of early or adjuvant antiandrogen therapy in prostate cancer. Patients with localized disease do not appear to derive clinical benefit from added bicalutamide. However, adding bicalutamide 150 mg to standard care provides significant clinical benefits in patients with locally advanced prostate cancer, irrespective of primary therapy." @default.
• W2117299097 created "2016-06-24" @default.
• W2117299097 creator A5028709604 @default.
• W2117299097 creator A5055216359 @default.
• W2117299097 creator A5058225499 @default.
• W2117299097 creator A5065289402 @default.
• W2117299097 creator A5081263517 @default.
• W2117299097 creator A5088713549 @default.
• W2117299097 date "2006-01-17" @default.
• W2117299097 modified "2023-10-16" @default.
• W2117299097 title "Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer" @default.
• W2117299097 cites W1830167702 @default.
• W2117299097 cites W1974256738 @default.
• W2117299097 cites W1985040614 @default.
• W2117299097 cites W1987876107 @default.
• W2117299097 cites W2012774668 @default.
• W2117299097 cites W2019370150 @default.
• W2117299097 cites W2024266959 @default.
• W2117299097 cites W2028129535 @default.
• W2117299097 cites W2028542256 @default.
• W2117299097 cites W2073336624 @default.
• W2117299097 cites W2074421032 @default.
• W2117299097 cites W2075132107 @default.
• W2117299097 cites W2086368563 @default.
• W2117299097 cites W2102015862 @default.
• W2117299097 cites W2103314990 @default.
• W2117299097 cites W2128365260 @default.
• W2117299097 cites W2134766389 @default.
• W2117299097 cites W2144498681 @default.
• W2117299097 cites W2228999161 @default.
• W2117299097 cites W2337912524 @default.
• W2117299097 doi "https://doi.org/10.1111/j.1464-410x.2005.06051.x" @default.
• W2117299097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16430622" @default.
• W2117299097 hasPublicationYear "2006" @default.
• W2117299097 type Work @default.
• W2117299097 sameAs 2117299097 @default.
• W2117299097 citedByCount "244" @default.
• W2117299097 countsByYear W21172990972012 @default.
• W2117299097 countsByYear W21172990972013 @default.
• W2117299097 countsByYear W21172990972014 @default.
• W2117299097 countsByYear W21172990972015 @default.
• W2117299097 countsByYear W21172990972016 @default.
• W2117299097 countsByYear W21172990972017 @default.
• W2117299097 countsByYear W21172990972018 @default.
• W2117299097 countsByYear W21172990972019 @default.
• W2117299097 countsByYear W21172990972020 @default.
• W2117299097 countsByYear W21172990972021 @default.
• W2117299097 countsByYear W21172990972022 @default.
• W2117299097 countsByYear W21172990972023 @default.
• W2117299097 crossrefType "journal-article" @default.
• W2117299097 hasAuthorship W2117299097A5028709604 @default.
• W2117299097 hasAuthorship W2117299097A5055216359 @default.
• W2117299097 hasAuthorship W2117299097A5058225499 @default.
• W2117299097 hasAuthorship W2117299097A5065289402 @default.
• W2117299097 hasAuthorship W2117299097A5081263517 @default.
• W2117299097 hasAuthorship W2117299097A5088713549 @default.
• W2117299097 hasBestOaLocation W21172990971 @default.
• W2117299097 hasConcept C121608353 @default.
• W2117299097 hasConcept C126322002 @default.
• W2117299097 hasConcept C126894567 @default.
• W2117299097 hasConcept C141071460 @default.
• W2117299097 hasConcept C142724271 @default.
• W2117299097 hasConcept C143998085 @default.
• W2117299097 hasConcept C197934379 @default.
• W2117299097 hasConcept C204787440 @default.
• W2117299097 hasConcept C207103383 @default.
• W2117299097 hasConcept C27081682 @default.
• W2117299097 hasConcept C2776141087 @default.
• W2117299097 hasConcept C2778375690 @default.
• W2117299097 hasConcept C2779322244 @default.
• W2117299097 hasConcept C2779466945 @default.
• W2117299097 hasConcept C2780192828 @default.
• W2117299097 hasConcept C2780962315 @default.
• W2117299097 hasConcept C44249647 @default.
• W2117299097 hasConcept C61367390 @default.
• W2117299097 hasConcept C71924100 @default.
• W2117299097 hasConceptScore W2117299097C121608353 @default.
• W2117299097 hasConceptScore W2117299097C126322002 @default.
• W2117299097 hasConceptScore W2117299097C126894567 @default.
• W2117299097 hasConceptScore W2117299097C141071460 @default.
• W2117299097 hasConceptScore W2117299097C142724271 @default.
• W2117299097 hasConceptScore W2117299097C143998085 @default.
• W2117299097 hasConceptScore W2117299097C197934379 @default.
• W2117299097 hasConceptScore W2117299097C204787440 @default.
• W2117299097 hasConceptScore W2117299097C207103383 @default.
• W2117299097 hasConceptScore W2117299097C27081682 @default.
• W2117299097 hasConceptScore W2117299097C2776141087 @default.
• W2117299097 hasConceptScore W2117299097C2778375690 @default.
• W2117299097 hasConceptScore W2117299097C2779322244 @default.
• W2117299097 hasConceptScore W2117299097C2779466945 @default.
• W2117299097 hasConceptScore W2117299097C2780192828 @default.
• W2117299097 hasConceptScore W2117299097C2780962315 @default.
• W2117299097 hasConceptScore W2117299097C44249647 @default.
• W2117299097 hasConceptScore W2117299097C61367390 @default.
• W2117299097 hasConceptScore W2117299097C71924100 @default.
• W2117299097 hasIssue "2" @default.
• W2117299097 hasLocation W21172990971 @default.
• W2117299097 hasLocation W21172990972 @default.

• next